Epithelial-mesenchymal transition is one of the critical cellular programs that facilitate the progression of breast cancer to an invasive disease. We have observed that the expression of N-myc interactor (NMI) decreases significantly during progression of breast cancer, specifically in invasive and metastatic stages. Recapitulation of this loss in breast cell lines with epithelial morphology (MCF10A (non-tumorigenic) and T47D (tumorigenic)) by silencing NMI expression causes mesenchymal-like morphological changes in 3D growth, accompanied by upregulation of SLUG and ZEB2 and increased invasive properties. Conversely, we found that restoring NMI expression attenuated the mesenchymal attributes of metastatic breast cancer cells, accompanied by distinctly circumscribed 3D growth with basement membrane deposition and decreased invasion. Further investigations into the downstream signaling modulated by NMI revealed that NMI expression negatively regulates SMAD signaling, which is a key regulator of cellular plasticity. We demonstrate that NMI blocks TGF-b/SMAD signaling via upregulation of SMAD7, a negative feedback regulator of the pathway. We also provide evidence that NMI activates STAT signaling, which negatively modulates TGF-b/ SMAD signaling. Taken together, our findings suggest that loss of NMI during breast cancer progression could be one of the driving factors that enhance the invasive ability of breast cancer by aberrant activation of TGF-b/SMAD signaling.
INTRODUCTION
One of the most lethal attributes of cancers such as breast cancer is its ability to spread to tissues far from its site of origin and colonize those tissues to form metastases. 1 In recent years, epithelial-to-mesenchymal transition (EMT) has received a great deal of attention because of its ability to impart invasive potential to otherwise confined epithelial cells within a carcinoma. 2, 3 The phenomenon of EMT was first observed when lens epithelial cells were suspended in a collagen matrix, and the cells dramatically changed morphology and lost their distinctive epithelial polarity. 4 Since that time, an enormous body of evidence has been generated that supports a physiological need for EMT, particularly in embryonic development and wound healing. 5 However, this otherwise elegant cellular program has also been implicated in pathologies, such as tissue fibrosis and cancer. 6, 7 EMT is involved in the progression of several solid tumors such as prostate cancer, pancreatic cancer, colon cancer and breast cancer. [8] [9] [10] [11] [12] [13] [14] Thus, it is vitally important to find novel molecules involved in both positive and negative regulation of EMT.
TGF-b/SMAD signaling is one of the central pathways involved in regulating EMT. TGF-b ligands from the tumor microenvironment activate TGF-b receptors, which in turn activate intracellular signal transducers, the SMAD family members, specifically R-SMAD 2 and 3. These together with SMAD 4 (co-SMAD) translocate to the nucleus and initiate a transcription program thought to be responsible for mesenchymal transition. The inhibitory SMADS, viz.SMADs 6 and 7, provide negative feedback to prevent aberrant activation of this pathway. 15 Abnormal activation of TGF-b signaling has been reported in late-stage cancers, including breast cancers. 16, 17 This activation has been one of the key events in rendering breast cells invasive and presumably facilitating the initiation of EMT. 18 In this study, we propose a novel regulator of the epithelial state in breast cancer, the N-Myc interactor (NMI). NMI was first identified as a molecule capable of interacting with N-Myc. 19 NMI is known to be capable of influencing important cellular signaling events such as modulation of STAT signaling 20 and negative regulation of hTERT transcription via its interaction with BRCA1. 21 We had previously observed that ectopic expression of NMI in highly tumorigenic and metastatic cell lines led to reduced in vivo tumor growth (in xenografts) and caused inhibition of Wnt/b-catenin signaling by enhancing degradation of non-membranous b-catenin. 22 Here we present our observations that NMI expression is compromised in advanced breast cancer. We describe that modulation of NMI levels alters epithelial attributes; specifically loss of NMI expression promotes EMT. Conversely, restoration of NMI expression inhibits the mesenchymal phenotype. We present evidence that these effects of NMI are mediated by its inhibitory activity on TGF-b/SMAD signaling.
RESULTS
NMI expression in breast cancer patients NMI levels in breast cancer specimens have never been evaluated. We assessed NMI expression at the transcript level by quantitative RT-PCR analysis ( Figure 1a) and at the protein level by immunohistochemically staining tissue microarrays (Figure 1b) . Our analysis revealed a noticeable reduction in NMI expression in invasive breast cancer. NMI transcript levels were significantly lower in grade 2 and grade 3 breast cancer specimens compared to the levels in normal breast tissue. Similarly, the immunohistochemical staining intensity and overall NMI staining showed a significant reduction in metastatic specimens as compared to the normal or fibroblastic breast tissue. We then analyzed the NMI protein level from 10 different breast cancer cell lines compared to human mammary epithelial lines (HME, HMEC and MCF10A). As shown in Figure 1c , some of these cell lines (MCF10CA.cl.d, MDA-MB-231, 2LMP) showed a noticeable reduction, others (MDA-MB-134, MDA-MB-453, MCF10CA.1a.cl.1) showed a total loss of NMI expression. However, there were some cell lines (MCF7, T47D, BT20, MDA-MB-468) that retained NMI expression. A closer look at the reported status of the morphologic status and invasive attributes of these cell lines (based on reports by Neve et al and Blick et al 23, 24 ) revealed that cell lines that display predominantly epithelial characteristics retain expression of NMI; however, cell lines that are mesenchymal-like display a noticeable loss of NMI protein expression (Table 1) .
Silencing NMI expression increases invasive ability To gain insight into the implications of loss of NMI expression, we stably silenced NMI expression from the human breast epithelial cell line, MCF10A (non-tumorigenic). Conversely, we stably restored NMI expression in its isogenic, tumorigenic and metastatic variant MCF10CA1.d (which expressed low endogenous levels of NMI). The resultant cell lines were termed as MCF10A-shNMI and MCF10CA1.d-NMI, respectively, and were tested for their invasive ability using a modified Boyden chamber assay. Our findings revealed that NMI-silenced cells showed approximately 2.2-fold increase in their invasive ability compared to the corresponding non-targeting control. In contrast, the NMI-overexpressing cells displayed reduced invasive ability (45% of control) (Figures 2a and b) .
Silencing NMI expression induces mesenchymal attributes Three-dimensional cell culture models provide an environment in which epithelial cells form spherical structures, exhibit apicalbasal polarity, and secrete a basement membrane that surrounds each structure. 25 Non-invasive cells display predominantly spherical structures that are well contained within their basement membranes. In contrast, invasive cells will detach from surrounding cells, degrade the basement membrane, and invade into the surrounding matrix. When tested for growth in 3D culture, the MCF10A non-targeting control-transfected cells predominantly showed well-preserved acinar structures, whereas MCF10A-shNMI formed invasive structures (Figure 2c ). Staining of these 3D structures for laminin-V to assess the integrity of the basement membrane revealed that although the non-targeting control cells had mostly intact basement membrane, MCF10A-shNMI had clearly discontinuous laminin-V staining indicative of a disrupted basement membrane (Figure 2c ). On the contrary, NMI expression in MCF10CA1.d elicited a dramatic change in both the size and shape of the resultant 3D structures. The MCF10CA1.d-NMI cells produced much smaller and highly circumscribed (wellpreserved ascinar structures) 3D structures, whereas the vector control cells produced large, irregularly shaped, branching structures ( Figure 2d ). There was minimal laminin-V staining of the control 3D structures, indicative of disrupted basement membrane, while the NMI-expressing cells showed noticeable restoration of basement membrane (Figure 2d) .
Examination of some of the key molecular attributes of EMT revealed that silencing NMI expression resulted in increased expression of EMT-inducing transcription factors. NMI-silenced MCF10A cells showed an increased expression of mesenchymal transcription factors SLUG and ZEB2 simultaneous with downregulation of E-cadherin and keratin-18 ( Figure 2e ). Conversely, expression of NMI in MCF10CA1.d decreased expression of EMT-inducing transcription factors SLUG and ZEB2 concomitant with increased expression of the epithelial marker keratin-18 ( Figure 2f ).
In corroboration with the NMI silencing effect observed in MCF10A, T47D-shNMI cells (generated by silencing NMI expression from tumorigenic, non-metastatic T47D breast cancer cells) showed increased invasive ability (Supplementary Figure 1A) . These cells also displayed altered cell morphology in 2D growth (tissue culture plates). NMI-silenced MCF10A and T47D cells showed more lanceolate (spindle-like) appearance resembling mesenchymal-like phenotype (Supplementary Figure 1B) . These spindle-like T47D-shNMI cells were noticeably devoid of E-cadherin staining (Supplementary Figure 1C) . Although there was no concomitant gain of N-cadherin or vimentin, we did notice a gain of expression of mesenchymal transcription factors (SLUG and SNAIL) (Supplementary Figure 1D) . NMI negatively regulates TGF-b/SMAD signaling The synergy between active TGF-b signaling and EMT is well documented; 26 more specifically, SLUG and ZEB2 expression are increased by active TGF-b/SMAD signaling. 27, 28 Thus, we pursued the possibility that NMI influences EMT by regulating TGF-b signaling. Evaluation of SMAD-mediated transcriptional activity using SBE-4 reporter assays revealed that silencing NMI expression enhanced SMAD-mediated transcription approximately fivefold in MCF10A and threefold in T47D. Conversely, NMI overexpression had a noticeable inhibitory effect on SMAD-mediated transcription, as seen by the suppressed SBE-4 activity in MCF10CA1.d NMI cells (Figure 3a) .
To confirm the effect of NMI expression on TGF-b signaling, we analyzed the levels of transcripts of known TGF-b/SMAD-driven transcription target genes (PLAU, PTHLH, TGFBI and TGFBR3). We observed that expression of these genes increased in NMI-silenced cells and decreased in NMI expressors (Figure 3b ), confirming that signaling through the TGF-b/SMAD was upregulated upon loss of NMI expression.
Abrogating NMI expression increased the invasive ability of MCF10A and T47D cells to an extent that was comparable to the respective shSCR cells treated with TGF-b1 ligand (Note: sh-NMI invasion value in the control group is comparable to the shScr values in the TGF-b1-treated group) (Figures 3c and d NMI regulates TGF-b/SMAD signaling via STAT5 mediated upregulation of SMAD7 NMI expression is upregulated by IFN-g. 22 Also, NMI has been shown to augment STAT5 signaling downstream of IFN-g. 20 Hence, we assessed the response of two different STAT5-regulated promoters, lactogenic hormone response element and b-casein, to STAT5 inhibitor treatment of MCF10CA1.d-NMI cells. We found that NMI expression led to a twofold increase in promoter activity of lactogenic hormone response element ( Figure 4a IFN-g/STAT signaling antagonizes TGF-b/SMAD signaling. 29, 30 This antagonistic effect has been attributed to IFN-g-mediated upregulation of an inhibitory SMAD, SMAD7. 31 In NMI-silenced cells SMAD7 protein levels were notably reduced, whereas NMI overexpression increased SMAD7 protein expression ( Figure 4e ). Hence, we used the approach of silencing SMAD7 expression in MCF10CA1.d-NMI cells to test its relevance to the signaling downstream of NMI. Upon SMAD7 silencing, these cells showed increased invasive ability (Figure 4f ) as well as increased expression of ZEB2 and the TGF-b target gene TGFBR3 (Figure 4g ). These observations indicate that upregulation of SMAD7 by NMI may mediate the negative impact of NMI on TGF-b/SMAD signaling.
DISCUSSION
Cellular plasticity observed in the trans-differentiation process of EMT is integral to development, but it is also recapitulated in invasion and metastasis of carcinomas. [32] [33] [34] EMT imparts invasive capacity to epithelial cells within a carcinoma, and thus it is thought to be a very important phenomenon underlying metastatic dissemination. A cell orchestrates this transition after integrating specific stimuli from several sources and converting those signals into distinct inter-and intra-cellular events. The best studied events are changes in gene expression that lead to functional phenotypic alterations. Several genes are repressed during EMT, including E-cadherin, the main molecular fastener of adherens junctions, and keratins (8 and 18), which are expressed by differentiated epithelial cells. Conversely, a host of genes are upregulated during EMT, several of which are transcription factors that mediate further downstream gene expression changes, whereas others are genes that directly aid the transition and provide the cell with the machinery necessary for becoming a mesenchymal cell. [35] [36] [37] Specifically of importance to this work, EMT has a key role in breast cancer progression. 9, 38 Several signaling pathways such as Wnt, NFkb, Hedgehog and Notch are significant drivers of EMT. 39 More importantly, TGF-b signaling has been shown to have a central role in EMT. Several studies support a critical role of SMADs in TGF-b-dependent EMT-associated tumor progression and metastasis. 26, 40, 41 For example, antagonizing SMAD signaling decreased metastatic potential of xenografted breast cancer cell lines, 42, 43 whereas overexpression of SMADs 2 and 3 resulted in increased EMT in a mammary epithelial model. 44, 45 Multiple transcription factors that promote induction of mesenchymal phenotype, such as ZEB1, ZEB2 and SNAI1, are induced by TGF-b/SMAD signaling and have critical roles in TGF-b-induced EMT. 40, 46 Thus overall, the TGF-b/SMAD signaling axis has a key role in regulating critical EMT genes and breast cancer progression. 47 Table1. Summary of reported epithelial/mesenchymal (E/M) natures of respective cell lines used in Figure 1c, BT-20 ****** E (NCad-) Low 7
MDA-MB-468
Abbreviation: NMI, N-myc interactor. NMI expression levels are depicted as an (*) using an arbitrary scale of 5* ¼ 100% for NMI expression in HME and HMEC cells. A '-' indicates absence of expression of NMI, whereas it indicates absence of information for 3D morphology and invasive ability and E/M nature.
Despite its reported interactions with several key players in tumor progression and metastasis, such as BRCA1, STATs, c-Myc, N-Myc, TIP60 and SOX10, only limited knowledge has been established about the mechanistic and functional role of NMI in tumor progression. We have discovered that NMI modulates TGFb/SMAD signaling. The enhanced invasive ability of NMI-silenced cells is completely abrogated by treatment with TGF-b inhibitors. The levels of inhibitory SMADs are critical to regulating SMAD signaling. SMAD7 is an inhibitory SMAD that is upregulated by NMI and antagonizes TGF-b signaling through multiple mechanisms. Overexpression of SMAD7 prevents injury-induced EMT of lens epithelial cells 48 and mammary epithelial cells. 45 SMAD7 binds the TGF-b type I receptor, interferes with recruitment, downstream phosphorylation and activation of the receptorSMADs, SMAD2 and 3. 49 In addition, SMAD7 functions to recruit E3 ubiquitin ligases to TGF-b type I receptor, resulting in its degradation. 50 Recent studies have demonstrated that repression of SMAD7 by the miR106b-25 cluster activates TGF-b signaling and induces EMT. 51 Both the TGF-b/SMAD and the prolactin/JAK/STAT pathway are critical to the proper development, maintenance and functioning of the mammary epithelial tissue. Interestingly, opposing physiological effects between these two signaling pathways are prominent in the regulation of mammary gland development. Activated receptor-SMADs inhibit STAT5 association with its coactivator CREB-binding protein, thus blocking STAT5 transactivation of its target genes and leading to inhibition of mammary gland differentiation and lactation. 52 In fact, STAT and SMAD signaling pathways crosstalk with each other with interweaved regulatory mechanisms. 53 NMI is an IFN-g upregulated protein 22 and hence it is noteworthy that IFN-g has been reported to abrogate TGF-b signaling. 30, 54 This antagonistic regulation of TGF-b/SMAD signaling by IFN/STAT signaling is due to upregulation of SMAD7. 31 Consistent with these reports, our studies reveal that NMI expression upregulates SMAD7 and this upregulation happens via enhancement of STAT signaling by NMI (In our system, expression of another inhibitory SMAD, SMAD6, did not change (data not shown). We have also shown that NMI has an inhibitory effect on Wnt/b-catenin signaling. 22 In that study, we had evaluated the functional implications of upregulation of NMI expression in MDA-MB-231 breast cancer cells and MDA-MB-435 cells. We had observed a significant reduction in primary tumor growth in xenograft studies. We analyzed MDA-MB-231-NMI (231-NMI) cells for SMAD signaling activity using SBE-4 luciferase reporter assays. Consistent with our observations, the cells restored for NMI significantly (65%) decreased the activity of SBE-4 (Supplementary Figure 2A) . We had previously reported that these 231-NMI cells lacked invasive ability. 22 When analyzed for the 3D growth morphology, 231-NMI cells showed a striking absence of invasive, stellate outgrowth in cells with gain of a basement membrane stained with lamininV (Supplementary Figure 2B) .
Histological analysis of slow-growing 231-NMI xenograft tumors compared to 231-Vector control tumors showed a well-circumscribed tumor with minimal inflammation of the stroma and minimal invasion of surrounding tissue (Supplementary Figure 2C) . These cells were also deficient in their ability to colonize the lungs (Supplementary Figure 2D) . This reduced experimental metastasis may be the result of negative effect on proliferation as a consequence of suppression of canonical Wnt signaling or it may be due to the reduced ability of 231-NMI cells to invade the lung tissue. Wnt/b-catenin signaling is also a critical player in promotion of the EMT program. Thus, the EMT effect upon loss of NMI could partly be a consequence of aberrant Wnt signaling. Several recent reports indicate that mesenchymal-epithelial transition (reversal of EMT) is necessary for overt metastatic growth. 35, 55, 56 However, the effect of re-expression of NMI after the tumor cells invade the metastatic niche needs further assessments.
Thus, we conclude that NMI is not just a binding partner of several transcription factors, but instead its expression has important functional consequences that affect malignant progression. Certainly, absence of NMI primes breast cancer cells to undergo EMT and prompts their metastatic dissemination. Our studies presented here provide a new insight into the role of the NMI as one of the gatekeepers of epithelial plasticity. Not only is this the first report of NMI regulating EMT, but it also pioneers the connection between NMI and the TGF-b signaling pathway. This exciting new discovery provides us with an insight into the mechanistic underpinnings of NMI's ability to have such profound effects on cellular behavior, consequently revealing how its absence may contribute to the invasion of breast tumors. This also suggests a possibility that absence of NMI may indicate poor prognosis.
MATERIALS AND METHODS
Cell culture and stable cell line selection HMEC and HME cell lines were grown in DMEM/F-12 (Life Technologies, Grand Island, NY, USA) supplemented with 10 ng/ml EGF (Sigma, St Louis, MO, USA), 500 ng/ml hydrocortisone (Sigma) and 10 mg/ml insulin (Sigma). MCF10A, MCF10CA1acl.1 and MCF10CAcl.d cells were grown in DMEM/F-12 supplemented with 5% horse serum (Life Technologies), 100 ng/ml cholera toxin (Sigma), 10 mg/ml insulin, 25 ng/ml EGF and 500 ng/ml hydrocortisone. T47D cells were grown in RPMI 1640 media (Life Technologies) supplemented with 10% FBS (Atlanta Biologicals, Norcross, GA, USA), 10 mg/ml insulin 
Immunohistochemistry
Tissue microarray sides were obtained from the National Cancer Institute CBTR. Slides were heated at 60 1C for 1 h, followed by paraffin removal with xylene and subsequent rehydration with Tris-buffered saline (TBS). Antigen retrieval was performed in a chamber containing citrate buffer (pH 6.0) for 20 min at 97 1C (DAKO PTlink, Carpinteria, CA, USA). Samples were blocked with 3% hydrogen peroxide and 10% goat serum for 10 min each at room temperature. Sections were incubated at room temperature in primary antibody (NMI monoclonal, Sigma-Aldrich, St Louis, MO, USA, 1:1200) for 30 min, an HRP-linked secondary antibody (Envision, DAKO) for 15 min, and 3,3-diaminobenzidine for 5 min. Samples were counterstained with hematoxylin, dehydrated and mounted with a cover slip. Staining was scored via the Allred system. All samples were digitally imaged and scored (Automated Cellular Imaging System, DAKO) with the assistance of our collaborating pathologist (JAT). A proportion score was assigned, which represents the estimated proportion of positive tumor cells on the entire slide as determined by the Automated Cellular Imaging System: no staining ¼ 0; 0 to less than 1% ¼ 1; 1% to less than 10% ¼ 2; 10% to less than 33.3% ¼ 3; 33.3% to less than 66.6% ¼ 4; over 66.6% ¼ 5. An intensity score, as determined by the Automated Cellular Imaging System, was obtained of the average staining intensity of positive tumor cells: negative ¼ 0; weak ¼ 1; intermediate ¼ 2; and strong ¼ 3. The proportion score and the intensity score were added to obtain a total score (range of 0-8).
Protein isolation and immunoblotting
Cell lysates were collected on ice using NP-40 alternative (EMD Chemicals) combined with protease and phosphatase inhibitors (EMD Chemicals). Cell lysates were incubated on ice for 2 h and then centrifuged at 13 000 r.p.m. for 30 min. Protein concentration was estimated using PrecisionRed (Cytoskeleton Inc., Denver, CO, USA). Lysates were resolved on SDS-PAGE gels and transferred to PVDF membrane (Bio-Rad Laboratories, Hercules, CA, USA). The membranes were blocked in either 5% non-fat dry milk or bovine serum albumin (Sigma-Aldrich), and probed with appropriate antibodies. The signal was visualized using SuperSignal West Dura (Thermo Scientific, Rockford, IL, USA) and documented using G:Box Chemi imager using the GeneSnap software (Syngene USA, Frederick, MD, USA).
Primary antibodies for KRT18 (#4546), SLUG (#9585), SNAIL (#3895), GAPDH (#2118L), SMAD6 (#9519), TGFBI (#5601), TGFBR3 (#5544), a/btubulin (#2148) (Cell Signaling Technology, Inc., Danvers, MA, USA) were used (dilution of 1:1000) in TBST (0.1% Tween) with 5% bovine serum albumin (Sigma-Aldrich). NMI (WH0009111M1) and ZEB2 (AV33694) primary antibodies (Sigma-Aldrich) were used in TBST (0.05% Tween) with 5% non-fat dry milk. The SMAD7 (MAB2029) and PLAU (MAB1310) primary antibodies (R&D Systems, Minneapolis, MN, USA) were used according to the manufacturer's recommendations. Anti-mouse (NA931V) and antirabbit (NA934V) secondary antibodies (GE Healthcare, Pittsburgh, PA, USA) were used at a 1:2500-1:5000 dilution.
Invasion assays
Cells suspended in serum-free media were seeded in Biocoat Matrigel invasion chambers (BD Biosciences, Sparks, MD, USA) according to the manufacturer's recommendations. Fibronectin (10 mg/ml) (BD Biosciences, Sparks, MD, USA) was used as the chemoattractant. Cells were incubated at 37 1C with 5% CO 2 for 10-12 h. After incubation, cells were fixed in 4% paraformaldehyde (Boston Bioproducts, Ashland, MA, USA) for 10 min at room temperature or overnight at 4 1C. Cells were then stained with crystal violet (BD Biosciences) for 10 min at room temperature, rinsed with water, and allowed to dry overnight before imaging. Images were obtained and invaded cells were counted using the NIS Elements software (Melville, NY, USA). Eight fields were counted for each group and statistical analysis was performed using GraphPad Prism software (Graphad, La Jolla, CA, USA). Significance was analyzed using one-way ANOVA and P-values were calculated using Bonferroni's Multiple Comparison Test.
3D cell culture
Cells suspended in growth media were seeded into an eight-chambered borosilicate cover glass system (Nalge Nunc International, Rochester, NY, USA) coated with 3D Culture Matrix reduced growth factor basement membrane extract (Trevigen Inc., Gaithersburg, MD, USA). Five thousand cells that were suspended in 400 ml of growth media supplemented with 2% 3D Culture Matrix were seeded in each chamber. Cells were incubated at 37 1C with 5% CO 2 and growth media was changed every 3-4 days. Images of the acinar structures were obtained 7-12 days after seeding (timing is cell-line dependent). Laminin-V was visualized using Alexa Fluor 488-conjugated anti-laminin-V (clone D4B5) (Millipore, Billerica, MA, USA) and nuclei were stained with Vectashield Hard Set Mounting Medium with DAPI (Vector Laboratories, Inc., Burlingame, CA, USA).
RNA isolation and quantitative real-time PCR
Total RNA was harvested using the RNEasy kit (Qiagen Inc., Valencia, CA, USA). RNA (2 mg) was transcribed into complementary DNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Quantitative real-time PCR was performed with TaqMan Universal PCR Master Mix (Applied Biosystems) in an iCycler iQ5 (Bio-Rad Laboratories) real-time PCR detection system. TaqMan Gene Expression Assays (Life Technologies) were used for the following genes: GAPDH (Hs99999905_m1), KRT18 (Hs01941416_g1), NMI (Hs00190768_m1), PLAU (Hs01547054_m1), SNAIL (Hs00195591_m1), SLUG (Hs00950344_m1), TGFBI (Hs00932747_m1), TGFBR3 (Hs01114253_m1), ZEB2 (Hs00207691_m1). Data collected were normalized to the endorsed control gene, GAPDH, and expressed as fold change in relative expression using the DDC t method (2 À DCt ).
Microscopy and imaging
Invasion assay images were obtained using a Nikon Eclipse TE2000-U. Images of two-dimensional cell culture were obtained with a Nikon Eclipse TS100. Images of three-dimensional cell culture were obtained using the Nikon Eclipse TE2000-E. All images were captured using the NIS Elements Advanced Research software (Nikon Inc., Melville, NY, USA).
Luciferase assays SMAD binding element luciferase construct was generated in the lab of Bert Vogelstein 57 and was obtained from Addgene (plasmid 16495). Assays were performed in 96-well plates with 20 000 cells seeded per well. The cells were allowed to attach overnight and were transfected the next day with 200 ng of plasmid DNA per well. Assays were terminated 48 h after transfection and luminescence was analyzed using the Luciferase Assay System on a Glomax 20/20 luminometer (Promega, Madison, WI, USA). Luminescence readings were normalized to total protein content in each well.
TGF-b inhibitors and ligands
Small-molecule inhibitors of the TGF-b signaling pathway were added independently to the cell culture media at various indicated concentrations. A8301 (2 mM) (Stemgent, San Diego, CA, USA) was used according to the manufacturer's recommendations. Recombinant human TGFB1 (#8915) (Cell Signaling Technology, Inc.) was used (5 ng/ml), unless otherwise indicated. For invasion assays, inhibitors or ligands were added at the same concentration to the serum-free media both in the chamber and in the well. Cells were not pre-treated. For the 3D cell culture, fresh inhibitors or ligands were added each time the media was changed (every 3-4 days). For standard 2D cell culture, fresh inhibitors or ligands were added each time the media was changed (every 3-5 days).
Immunocytochemistry
Cells were seeded at 30 000 cells per well in a 24-well plate with a 12-mm round poly-lysine-coated glass coverslip. Cells after 4% paraformaldehyde fixation, coverslips were washed three times in PBS and then blocked with 5% BSA in PBS with 0.3% Triton X-100 for 1 h at room temperature with gentle shaking. Anti E-cadherin antibody (Cell Signaling, Inc. 1:200) was diluted in 1% BSA in PBS with 0.3% Triton X-100 overnight with gentle shaking at 4 1C. Coverslips were then washed PBS and incubated for 1 h at room temperature with anti-rabbit Alexa-Fluor 488 (1:400) in 1% BSA in PBS with 0.3% Triton X-100. Coverslips were washed PBS and mounted using VectaShield.
